<DOC>
	<DOCNO>NCT02239861</DOCNO>
	<brief_summary>This clinical trial patient solid tumor come back , may come back , go away treatment , include standard treatment know diseases . This study use special immune system cell call tumor-associated antigen ( TAA ) -specific cytotoxic T lymphocyte , new experimental therapy . The protein investigator target study call tumor-associated antigen ( TAAs ) . These cell proteins specific cancer cell , either show show low quantity normal human cell . In study , investigator target five common TAAs call NY-ESO-1 , MAGEA4 , PRAME , Survivin SSX . On different study , patient treat far treatment show safe . The investigator want try treatment patient solid tumor . This protocol design Phase I dose-escalation study .</brief_summary>
	<brief_title>TAA-Specific CTLS Solid Tumors ( TACTASOM )</brief_title>
	<detailed_description>Blood collect patient TAA-specific CTLs make . The cell inject IV patient 1 - 10 minute . The patient may pre-treated acetaminophen ( Tylenol ) diphenhydramine ( Benadryl ) . Acetaminophen ( Tylenol ) diphenhydramine ( Benadryl ) give prevent possible allergic reaction T cell infusion . Initially , two dos T cell give two week apart . The patient 's disease assess pre-infusion 6 week second infusion . If second infusion reduction size patient 's tumor CT MRI scan assess radiologist , patient receive six ( 6 ) additional dos T cell monthly interval wish . All treatment give Center Cell Gene Therapy Houston Methodist Hospital Texas Children 's Hospital . In first second T cell infusion , 6 week last infusion , investigator ask patient receive anti-cancer treatment , radiation therapy chemotherapy , except PD1/PDL1 inhibitor clinically indicate . If patient receive therapy in-between first second infusion T cell , take treatment able receive second infusion T cell . This dose escalation study . This mean beginning , patient start low dose ( 1 4 different level ) T cell . Once dose schedule prove safe , next group patient start high dose . This process continue 4 dose level study . If side effect severe , dose lower T cell injection stop . Medical test treatment : Physical exam . Blood test measure blood cell , kidney liver function . Measurements patient 's tumor routine image study . The investigator use image study previously perform follow patient 's tumor : Computer Tomogram ( CT ) , Magnetic Resonance Imaging ( MRI ) , Positron Emission Tomography ( PET ) . Pregnancy test patient female child . Medical test treatment : Blood test measure blood cell , kidney liver function . Imaging study 8 week 1st CTL infusion . To learn way T cell work patient 's body , extra 20-40 mL ( 4-8 teaspoon ) blood take infusion , Weeks 1 , 2 , 4 6 . Afterwards , blood collect 3 , 6 , 9 12 month last infusion . The investigator use blood see long T cell last , look immune response patient 's response cancer . Patients contact year 4 additional year ( total 5 year follow-up ) evaluate disease response long-term .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>THIS PROTOCOL IS CURRENTLY NOT RECRUITING ADULTS . Procurement 1 . Any patient regardless sex solid tumor express follow antigen ( PRAME , SSX2 , MAGEA4 , NYESO11 and/or Survivin ) : 1 . Active disease first line therapy ; 2 . Refractory disease ; 3 . As adjuvant therapy high risk disease ( high risk disease disease &gt; 50 % risk progression within 5 year ) 2 . Patients life expectancy least 6 week . 3 . Age great equal 2 less equal 80 year old . 4 . Hgb &gt; 8.0 5 . Informed Consent explain , understood sign patient/guardian . Patient/guardian give copy inform consent . Procurement 1 . Diagnosis primary CNS tumor . 2 . Patients severe intercurrent infection . 3 . Patients active HIV infection time procurement ( pending time blood draw ) . 4 . Patients remission enrol another study time progression diseasefree survival primary endpoint . Treatment 1 . Any patient regardless sex solid tumor express follow antigen ( PRAME , SSX2 , MAGEA4 , NYESO11 and/or Survivin ) : 1 . Active disease first line therapy ; 2 . Refractory disease ; 3 . As adjuvant therapy high risk disease ( high risk disease disease &gt; 50 % risk progression within 5 year ) 2 . Patients life expectancy least 6 week . 3 . Age great equal 2 less equal 80 year old . 4 . Pulse oximetry &gt; 95 % room air patient previously receive radiation therapy . 5 . Patients Karnofsky/Lansky score great equal 50 . 6 . Patients bilirubin less equal 2x upper limit normal , AST le equal 3x upper limit normal , Hgb &gt; 8.0 7 . Patients creatinine less equal 2x upper limit normal age . 8 . Patients investigational therapy one month prior entry study . 9 . Patients conventional therapy least 1 week prior entry study . PD1/PDL1 inhibitor allow medically indicate . 10 . Informed Consent explain , understood sign patient/guardian . Patient/guardian give copy inform consent . 11 . Due unknown effect therapy fetus , pregnant woman exclude research . The male partner use condom Females childbearing potential must willing utilize one effective birth control method study unless female hysterectomy tubal ligation . Treatment 1 . Diagnosis primary CNS tumor . 2 . Patients severe intercurrent infection . 3 . Patients receive systemic corticosteroid ( patient steroid least 48 hour eligible ) . 4 . Pregnant breastfeed 5 . HIV positive . 6 . Patients remission enrol another study time progression diseasefree survival primary endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Bladder cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Endometrial cancer</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Head neck cancer</keyword>
	<keyword>HCC</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>Sarcoma ( osteo- , synovial , rhabdomyo- , etc )</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>Thyroid cancer</keyword>
	<keyword>cytotoxic T lymphocyte</keyword>
</DOC>